DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2023 in Amgen Lawsuit - AMGN

New York, New York--(Newsfile Corp. - March 28, 2023) - Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit.

The lawsuit on behalf of Amgen investors has been commenced in the the United States District Court for the Southern District of New York. This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/amgen-class-action-loss-submission-form?prid=37805&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Amgen Inc. NEWS - AMGN NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) the U.S. government claimed Amgen owed more than $3 billion in back taxes for tax years 2010, 2011, and 2012; (b) the U.S. government claimed Amgen owed more than $5 billion in back taxes for tax years 2013, 2014, and 2015; (c) the U.S. government would likely claim Amgen owed materially more to the U.S. government than investors had been led to believe for subsequent tax years for which the Company had used the same profit allocation treatment between its U.S. and Puerto Rico operations; (d) Amgen had not taken sufficient accruals to account for its outstanding tax liabilities; (e) Amgen had failed to comply with Accounting Standards Codification Topic 450 and other rules and regulations regarding the preparation of its periodic filings with the U.S. Securities and Exchange Commission; and (f) Amgen's refusal to pay taxes claimed by the U.S. government exposed the Company to a substantial risk of severe financial penalties imposed by the Internal Revenue Service.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Amgen during the relevant timeframe, you have until May 12, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://zlk.com/pslra-1/amgen-class-action-loss-submission-form?prid=37805&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/160334